DaVita Inc. (NYSE:DVA) Shares Acquired by Brandywine Global Investment Management LLC

Brandywine Global Investment Management LLC grew its stake in DaVita Inc. (NYSE:DVA) by 68.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 108,272 shares of the company’s stock after buying an additional 44,005 shares during the period. Brandywine Global Investment Management LLC owned 0.13% of DaVita worth $16,192,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its position in DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after acquiring an additional 92,014 shares during the period. Amundi raised its stake in shares of DaVita by 116.4% in the fourth quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after purchasing an additional 240,126 shares during the last quarter. KBC Group NV lifted its holdings in shares of DaVita by 0.8% during the fourth quarter. KBC Group NV now owns 316,155 shares of the company’s stock worth $47,281,000 after purchasing an additional 2,636 shares during the period. Nordea Investment Management AB boosted its position in DaVita by 4.9% in the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company’s stock valued at $39,712,000 after buying an additional 12,339 shares during the last quarter. Finally, California Public Employees Retirement System increased its holdings in DaVita by 75.1% in the 4th quarter. California Public Employees Retirement System now owns 196,788 shares of the company’s stock worth $29,430,000 after buying an additional 84,375 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on DVA. StockNews.com cut shares of DaVita from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. Barclays upped their price target on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Cowen reiterated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on DaVita in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $166.33.

DaVita Stock Down 1.5 %

DVA opened at $150.29 on Monday. The company has a fifty day moving average of $157.39 and a two-hundred day moving average of $157.55. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. DaVita Inc. has a fifty-two week low of $125.64 and a fifty-two week high of $179.60. The stock has a market capitalization of $12.02 billion, a price-to-earnings ratio of 13.99, a PEG ratio of 1.07 and a beta of 0.99.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.